Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs

Int J Pharm. 2014 Jul 1;468(1-2):105-11. doi: 10.1016/j.ijpharm.2014.04.027. Epub 2014 Apr 16.

Abstract

The main objectives of the present study were (i) to evaluate the effect of the mucus layer on saquinavir-loaded nanostructured lipid carriers (SQV-NLCs) uptake and (ii) to evaluate the mucopenetrating properties of dextran-protamine (Dex-Prot) coating on NLCs as per SQV permeability enhancement. Three different NLC formulations differing on particle size and surfactant content were obtained and coated with Dex-Prot complexes. SQV permeability was then evaluated across Caco-2 cell monolayers (enterocyte-like model) and Caco-2/HT29-MTX cell monolayers (mucus model). In the Caco-2 monolayers, Dex-Prot-NLCs increased up to 9-fold SQV permeability in comparison to uncoated nanoparticles. In the Caco-2/HT29-MTX monolayers, Dex-Prot-NLCs presenting a surface charge close to neutrality significantly increased SQV permeability. Hence, Dex-Prot complex coating is a promising strategy to ensure successful nanoparticle mucus-penetration, and thus, an efficient nanoparticle oral delivery. To our knowledge, this is the first time that Dex-Prot coating has been described as a nanoparticle muco-penetration enhancer across the intestinal mucus barrier.

Keywords: Caco-2; HT29-MTX; Mucus; NLCs; Permeability; Saquinavir.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Caco-2 Cells
  • Chemistry, Pharmaceutical
  • Dextrans / chemistry*
  • Drug Carriers*
  • Enterocytes / metabolism*
  • HT29 Cells
  • Humans
  • Intestinal Absorption
  • Mucus / metabolism*
  • Nanostructures
  • Nanotechnology
  • Particle Size
  • Permeability
  • Protamines / chemistry*
  • Saquinavir / chemistry
  • Saquinavir / metabolism*
  • Surface Properties
  • Surface-Active Agents / chemistry
  • Technology, Pharmaceutical / methods

Substances

  • Dextrans
  • Drug Carriers
  • Protamines
  • Surface-Active Agents
  • Saquinavir